Furthermore, the accumulation of the YAP/TAZ complex led to BRAF inhibitor resistance via increasing actin remodeling in melanoma (23), while in MM, BRAFV600E mutation was widely detected and posed as a druggable target in extramedullary invasion especially in the central nervous system (24), which indicated that further studies should be performed to investigate the predictive ability of YAP1 in BRAF inhibitor sensitivity in EM cases. The gene discussed is BRAF; the disease is Miyoshi myopathy.